Exact Sciences Corporation (EXAS) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
↓
56.10
↓-72% vs avg
5yr avg: 203.32
30Y Low53.7·High138.8
P/B Ratio
↑
8.24
↑+77% vs avg
5yr avg: 4.67
30Y Low2.4·High18.2
ROE
↑
-8.7%
↓+53% vs avg
5yr avg: -18.6%
30Y Low-497%·High-7%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
EXAS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Exact Sciences Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 56.1x P/FCF, 72% below the 5-year average of 203.3x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $20.0B | $19.2B | $10.4B | $13.3B | $8.7B | $13.3B | $20.0B | $12.1B | $7.7B | $6.1B | $1.4B |
| Enterprise Value | $21.6B | $20.7B | $12.5B | $15.3B | $10.9B | $15.4B | $20.9B | $12.9B | $8.2B | $6.0B | $1.3B |
| P/E Ratio → | -95.37 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.16 | 5.90 | 3.75 | 5.33 | 4.19 | 7.55 | 13.43 | 13.85 | 16.97 | 22.85 | 13.76 |
| P/B Ratio | 8.24 | 7.98 | 4.31 | 4.24 | 2.87 | 3.94 | 8.96 | 5.31 | 11.32 | 11.68 | 4.08 |
| P/FCF | 56.10 | 53.71 | 138.84 | 417.40 | — | — | 277.61 | — | — | — | — |
| P/OCF | 40.73 | 38.99 | 49.16 | 85.36 | — | — | 146.72 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EXAS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.38 | 4.53 | 6.11 | 5.25 | 8.72 | 13.99 | 14.74 | 18.13 | 22.58 | 13.32 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 58.10 | 167.73 | 478.45 | — | — | 289.25 | — | — | — | — |
EXAS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Exact Sciences Corporation earns an operating margin of -6.4%. Operating margins have expanded from -8.6% to -6.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -8.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.7% | 69.7% | 69.5% | 70.5% | 68.3% | 74.0% | 76.2% | 75.3% | 74.0% | 70.2% | 54.5% |
| Operating Margin | -6.4% | -6.4% | -38.0% | -8.6% | -28.5% | -48.4% | -51.5% | -26.7% | -35.1% | -44.5% | -170.1% |
| Net Profit Margin | -6.4% | -6.4% | -37.3% | -8.2% | -29.9% | -33.7% | -55.2% | -24.3% | -38.5% | -43.0% | -168.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.7% | -8.7% | -37.1% | -6.6% | -19.4% | -21.2% | -36.4% | -14.4% | -29.2% | -26.7% | -50.5% |
| ROA | -3.5% | -3.5% | -16.6% | -3.2% | -9.7% | -10.3% | -19.5% | -8.5% | -16.5% | -23.5% | -45.1% |
| ROIC | -3.6% | -3.6% | -16.3% | -3.1% | -8.3% | -15.0% | -18.8% | -8.2% | -14.4% | -24.0% | -43.4% |
| ROCE | -4.0% | -4.0% | -18.8% | -3.7% | -9.9% | -16.4% | -20.3% | -10.0% | -16.6% | -27.0% | -49.4% |
EXAS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $1.6B ($2.5B total debt minus $956M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.05 | 1.05 | 1.15 | 0.81 | 0.80 | 0.70 | 1.04 | 0.42 | 1.01 | 0.01 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.65 | 0.90 | 0.62 | 0.72 | 0.61 | 0.38 | 0.34 | 0.78 | -0.14 | -0.13 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 4.39 | 28.89 | 61.05 | — | — | 11.64 | — | — | — | — |
| Interest Coverage | — | — | -32.80 | -8.80 | -42.68 | -66.44 | -44.84 | -4.58 | -4.33 | -574.32 | -793.50 |
EXAS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Exact Sciences Corporation's current ratio of 2.43x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.32x to 2.43x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.43 | 2.43 | 2.15 | 2.32 | 2.38 | 2.76 | 3.47 | 2.34 | 8.99 | 7.15 | 10.87 |
| Quick Ratio | 2.17 | 2.17 | 1.92 | 2.07 | 2.09 | 2.56 | 3.33 | 2.08 | 8.70 | 6.77 | 10.65 |
| Cash Ratio | 1.50 | 1.50 | 1.42 | 1.51 | 1.53 | 1.99 | 2.91 | 1.37 | 8.23 | 6.23 | 10.14 |
| Asset Turnover | — | 0.55 | 0.47 | 0.39 | 0.33 | 0.26 | 0.30 | 0.25 | 0.30 | 0.44 | 0.26 |
| Inventory Turnover | 5.92 | 5.92 | 5.17 | 5.79 | 5.59 | 4.37 | 3.84 | 3.51 | 3.01 | 3.04 | 6.61 |
| Days Sales Outstanding | — | 33.57 | 32.94 | 29.73 | 27.68 | 44.75 | 57.07 | 54.30 | 36.41 | 36.25 | 31.32 |
EXAS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Exact Sciences Corporation returns 0.1% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 1.8% | 1.9% | 0.7% | 0.2% | — | — | 0.4% | — | — | — | — |
| Buyback Yield | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Shares Outstanding | — | $189M | $184M | $180M | $176M | $171M | $151M | $131M | $122M | $116M | $102M |
Peer Comparison
Compare EXAS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 EXASYou | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 GH | $12B | -27.8 | — | — | 64.5% | -44.4% | — | -34.9% | — |
 NTRA | $31B | -144.6 | — | 285.5 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 LH | $21B | 24.7 | 12.7 | 17.6 | 26.8% | 10.9% | 10.5% | 7.8% | 3.3 |
 DGX | $21B | 21.8 | 12.7 | 15.5 | 31.9% | 14.5% | 14.0% | 8.8% | 3.2 |
 NEOG | $2B | -1.8 | 20.7 | — | 47.1% | 1.1% | -41.9% | 0.2% | 6.8 |
 CDNA | $1B | -53.6 | — | 30.7 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $124B | 34.9 | 18.2 | 23.6 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 BIO | $7B | 9.2 | 16.7 | 18.5 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
Full EXAS Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See EXAS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EXAS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EXAS vs GH
Side-by-side business, growth, and profitability comparison vs Guardant Health, Inc..
Start ComparisonEXAS — Frequently Asked Questions
Quick answers to the most common questions about buying EXAS stock.
What is Exact Sciences Corporation's P/E ratio?
Exact Sciences Corporation's current P/E ratio is -95.4x. This places it at the 50th percentile of its historical range.
What is Exact Sciences Corporation's ROE?
Exact Sciences Corporation's return on equity (ROE) is -8.7%. The historical average is -66.0%.
Is EXAS stock overvalued?
Based on historical data, Exact Sciences Corporation is trading at a P/E of -95.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Exact Sciences Corporation's profit margins?
Exact Sciences Corporation has 69.7% gross margin and -6.4% operating margin.